Last reviewed · How we verify
NCT07503769: CHU-VA
CHU Dual-Energy Ablation in Ventricular Arrhythmia
NA trial testing ablation in Premature Ventricular Contractions in 10 participants. Enrolling by invitation.
31 July 2026
Quick facts
| Lead sponsor | Shanghai MicroPort EP MedTech Co., Ltd. |
|---|---|
| Phase | NA |
| Status | ENROLLING BY INVITATION |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 10 |
| Start date | 3 February 2026 |
| Primary completion | 31 July 2026 |
| Estimated completion | 31 October 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- ablation
Conditions studied
- Premature Ventricular Contractions — all drugs for Premature Ventricular Contractions →
- Ventricular Tachycardia — all drugs for Ventricular Tachycardia →
Sponsor
Shanghai MicroPort EP MedTech Co., Ltd. — full company profile →
Who can join
Adults 18 to 75, any sex, with Premature Ventricular Contractions or Ventricular Tachycardia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The objective of this study is to evaluate the safety of the dual-energy ablation catheter manufactured by Shanghai MicroPort EP Medical Technology Co., Ltd. in the treatment of tachyarrhythmias.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07503769
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of ablation
Trials testing the same drug.
- NCT07517640 — Combining Furmonertinib With Local Therapy for Inoperable Early-stage Lung Cancer: A Phase II Trial · Phase 2 · not yet recruiting
- NCT07487662 — TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcin · Phase 2 · not yet recruiting
- NCT05803928 — Ablation in Combination With Lenvatinib and Anti-PD-1 Antibodies · Phase 1 · recruiting
- NCT05643209 — Brugada Syndrome Substrate Characterization and Ablation · NA · recruiting
- NCT05097417 — Traditional Chinese Medicine Combined With Thermal and Cold Ablation for Early-stage Lung Cancer · NA · unknown
Other recruiting trials for Premature Ventricular Contractions
Currently open trials in the same condition.
- NCT07201506 — Real-Time Intracardiac Echocardiography for Ventricular Arrhythmia Ablation · NA · recruiting
- NCT06898281 — Intracardiac Echocardiography-Guided Catheter Ablation for Premature Ventricular Contractions Originating From the Papil · NA · active not recruiting
- NCT06146556 — Concealed Myocardial Abnormalities by Cardiac Magnetic Resonance Imaging in Idiopathic VT · active not recruiting
Other Shanghai MicroPort EP MedTech Co., Ltd. trials
Trials by the same sponsor.
- NCT07067372 — Clinical Study on the Safety and Efficacy of a New Magnetic Navigation Radiofrequency Ablation Catheter for Rapid Arrhyt · NA · not yet recruiting
- NCT07039032 — A Clinical Study on the Use of a Domestically Produced Three-dimensional Cardiac Electrophysiological Mapping System Com · NA · not yet recruiting
- NCT07036068 — A Clinical Study on the Use of a Domestically Produced Cryoablation System Combined With Balloon Cryoablation Technology · NA · not yet recruiting
- NCT07032948 — Safety and Efficacy Study of the First Domestically Produced FireMagic™ PreciSense™ 3D Microelectrode Ablation Catheter · NA · not yet recruiting
- NCT07079813 — Clinical Study on the Efficiency of Rapid Arrhythmia Mapping Using EasyStars™ High Density Mapping Catheter Applications · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07503769 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai MicroPort EP MedTech Co., Ltd.
- Last refreshed: 31 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07503769.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing